83
Participants
Start Date
August 17, 2018
Primary Completion Date
November 21, 2022
Study Completion Date
November 21, 2022
Retifanlimab
"Part 1: INCMGA00012 at the protocol-defined starting dose administered intravenously every 4 weeks, with dose escalation to determine the maximum tolerated dose.~Part 2: INCMGA00012 at the recommended dose from Part 1."
Epacadostat
"Part 1: Epacadostat at the protocol-defined starting dose administered orally twice daily, with dose escalation to determine the maximum tolerated dose.~Part 2: Epacadostat at the recommended dose from Part 1."
INCB050465
Part 1: INCB050465 at the protocol-defined starting dose administered orally once daily, with dose escalation to determine the maximum tolerated dose. Part 2: INCB050465 at the recommended dose from Part 1.
Roswell Park Cancer Institute, Buffalo
Upmc Cancercenter, Pittsburgh
Hospital of the University of Pennsylvania, Philadelphia
University of Florida - Shands Cancer Center, Gainesville
University of Chicago Medical Center, Chicago
South Texas Accelerated Research Therapeutics, San Antonio
The Angeles Clinic and Research Institute, Los Angeles
Yale New Haven Hospital, New Haven
Rutgers Cancer Institute of Nj, New Brunswick
Lead Sponsor
Incyte Corporation
INDUSTRY